RT Journal Article
T1 Functional respiratory impairment and related factors in patients with interstitial pneumonia with autoimmune features (IPAF): Multicenter study from NEREA registry
A1 Nieto Barbero, María Asunción
A1 Sanchez-Pernaute, Olga
A1 Vadillo, Cristina
A1 Rodriguez-Nieto, Maria Jesus
A1 Romero-Bueno, Fredeswinda
A1 López-Muñiz, Belen
A1 Cebrian, Laura
A1 Rio-Ramirez, Maria Teresa
A1 Laporta, Rosalia
A1 Bonilla, Gema
A1 Cobo, Tatiana
A1 Leon, Leticia
A1 Abasolo, Lydia
A1 Nieto, Maria Asuncion
A1 Vadillo, Cristina
A1 Lores, Irene Martín
A1 de Castro, Ana Bustos Garcia
A1 Romero Bueno, Fredeswinda
A1 Rodriguez Nieto, Maria Jesus
A1 Pernaute, Olga Sanchez
A1 Palacios, Carmelo
A1 Carrera, Luis Gomez
A1 Bonilla, Gema
A1 Ortega, Gemma Mora
A1 Cobo, Tatiana
A1 López Muñiz, Belén
A1 Cebrián, Laura
A1 Godoy, Hilda
A1 Laporta, Rosalia
A1 Cubas, Irene Llorente
A1 Valenzuela, Claudia
A1 de Vicuña, Rosario Garcia
A1 Jauregui, Ana
A1 Rigual, Juan
A1 Martos, Jesús Loarce
A1 Hita, Jose Luis Morell
AB Background The objective of the present study is to describe the characteristics of interstitial pneumonia withautoimmune features (IPAF) patients, to assess the incidence rate of functional respiratory impairment over time andto evaluate the influence of therapeutic alternatives on the prognosis of these patients.Methods A longitudinal observational multicenter study was performed (NEREA registry). It was carried out by amultidisciplinary team in seven Hospitals of Madrid. Patients were included from IPAF diagnosis. Main outcome: poorprognosis as functional respiratory impairment (relative decline in FVC % defined as≥5% every 6 months). Covariates:therapy, sociodemographic, clinical, radiological patterns, laboratory and functional tests. Statistics: Survival tech‑niques were used to estimate IR per 100 patients-semester with their 95% confidence interval [CI]. The influence ofcovariates in prognosis were analyzed through cox multivariate regression models (hazard ratio (HR) and [CI]).Results 79 IPAF were included, with a mean and a maximum follow-up of 3.17 and 12 years respectively. Alongthe study, 77.2% received treatment (52 glucocorticoids, 25 mycophenolate, 21 azathioprine, 15 rituximab and 11antifibrotics). IR was 23.9 [19.9–28.8], and 50% of IPAF developed functional respiratory impairment after 16 monthsfrom its diagnosis. Multivariate analysis: usual interstitial pneumonia (UIP) had poorer prognosis compared to nonspecific interstitial pneumonia (NSIP) (p=0.001). In NSIP, positive ANA, increased the risk of poor prognosis. In UIP,glucocorticoids (HR: 0.53 [0.34–0.83]), age (HR: 1.04 [1.01–1.07]), and Ro-antibodies (HR: 0.36 [0.19–0.65]) influencedthe prognosis.Conclusions IPAF have functional impairment during the first years of disease. Factors predicting deterioration differ
PB Springer Nature
SN 1465-993X
YR 2023
FD 2023-01-18
LK https://hdl.handle.net/20.500.14352/134799
UL https://hdl.handle.net/20.500.14352/134799
LA eng
NO Nieto, M.A., Sanchez-Pernaute, O., Vadillo, C. et al. Functional respiratory impairment and related factors in patients with interstitial pneumonia with autoimmune features (IPAF): Multicenter study from NEREA registry. Respir Res 24, 19 (2023). https://doi.org/10.1186/s12931-023-02317-5
DS Docta Complutense
RD 27 abr 2026